Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | HPGD | P15428 | 4/20 | 0.33 |
| ▸ | GAA | P10253 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16931254 | 0.79 | GAA (0.41) | KDM4EHPGDGAAALDH1A1LMNA | |
| SCHEMBL2241228 | 0.74 | ALDH1A1 (0.50) | KDM4EHPGDGAAALDH1A1LMNA | |
| SCHEMBL18220609 | 0.71 | — | — | |
| SCHEMBL5911639 | 0.68 | LMNA (0.47) | KDM4EHPGDGAAALDH1A1LMNA | |
| SCHEMBL31756597 | 0.67 | ALDH1A1 (0.33) | HPGDGAAALDH1A1KMT2AMEN1 | |
| SCHEMBL1744112 | 0.64 | — | — | |
| SCHEMBL1786936 | 0.64 | HDAC9 (0.44) | FFAR3LMNA | |
| Hydrochloric Acid SCHEMBL9526798 | 0.63 | HDAC9 (0.43) | FFAR3LMNA | |
| SCHEMBL664817 | 0.63 | ESR2 (0.31) | — | |
| SCHEMBL16426789 | 0.61 | FFAR3 (0.41) | FFAR3KDM4EALDH1A1SMN1; SMN2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3310775-B1 | 3-AMINO-1,5,6,7-TETRAHYDRO-4H-INDOL-4-ONES | Bayer Pharma AG (DE) | 2020-04-01 | — | — | EP | disclosed |
| US-10227299-B2 | 3-amino-1,5,6,7-tetrahydro-4H-indol-4-ones | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-03-12 | — | — | US | disclosed |
| US-20180155285-A1 | 3-AMINO-1,5,6,7-TETRAHYDRO-4H-INDOL-4-ONES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-06-07 | — | — | US | disclosed |
| EP-3310775-A1 | 3-AMINO-1,5,6,7-TETRAHYDRO-4H-INDOL-4-ONES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-04-25 | — | — | EP | disclosed |
| WO-2016202755-A1 | 3-AMINO-1,5,6,7-TETRAHYDRO-4H-INDOL-4-ONES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10227299-B2 | 3-amino-1,5,6,7-tetrahydro-4H-indol-4-ones | MYC, HCCS, MCL1 | FFAR3 4019/4885KDM4E 919/4885HPGD 820/4885 |
| US-20180155285-A1 | 3-AMINO-1,5,6,7-TETRAHYDRO-4H-INDOL-4-ONES | HCCS, MCL1, MKI67 | FFAR3 3767/4885KDM4E 961/4885HPGD 1117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.